The firm owns a Beta (Systematic Risk) of -0.1643, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning YS Biopharma are expected to decrease at a much lower rate. During the bear market, YS Biopharma is likely to outperform the market. Even though it is essential to pay attention to YS Biopharma existing price patterns, it is always good to be careful when utilizing equity price patterns. Our approach towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. YS Biopharma exposes fifteen different technical indicators, which can help you to evaluate its performance. YS Biopharma has an expected return of -1.0%. Please make sure to check out YS Biopharma Co standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if YS Biopharma performance from the past will be repeated at some future date.
YS Biopharma Performance
0 of 100
Over the last 90 days YS Biopharma Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
|YS Biopharma Announces First Subject Enrollment in Pivotal Phase ... - Marketscreener.com|
|Noble Capital Markets Initiates Coverage on YS Biopharma With ... - Marketscreener.com|
|Begin Period Cash Flow||271.1 M|
YS Biopharma Relative Risk vs. Return LandscapeIf you would invest 112.00 in YS Biopharma Co on September 7, 2023 and sell it today you would lose (58.00) from holding YS Biopharma Co or give up 51.79% of portfolio value over 90 days. YS Biopharma Co is generating negative expected returns and assumes 5.4995% volatility on return distribution over the 90 days horizon. Put differently, 48% of stocks are less risky than YS Biopharma on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Allowing for the 90-day total investment horizon YS Biopharma is expected to under-perform the market. In addition to that, the company is 7.0 times more volatile than its market benchmark. It trades about -0.18 of its total potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.04 per unit of volatility.
YS Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for YS Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as YS Biopharma Co, and traders can use it to determine the average amount a YS Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
YS Biopharma Fundamentals Growth
YS Biopharma Stock prices reflect investors' perceptions of the future prospects and financial health of YS Biopharma, and YS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on YS Biopharma Stock performance.
About YS Biopharma Performance
Things to note about YS Biopharma performance evaluationChecking the ongoing alerts about YS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for YS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions. Evaluating YS Biopharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate YS Biopharma's stock performance include:
- Analyzing YS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether YS Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining YS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating YS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of YS Biopharma's management team can help you assess the company's leadership.
- Pay attention to analyst opinions and ratings of YS Biopharma's stock. These opinions can provide insight into YS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for YS Biopharma Stock analysis
When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
Quarterly Revenue Growth
Return On Equity
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.